FDA Phase IV Enforcement Powers Needed In PDUFA III, Rep. Stupak Says
Executive Summary
FDA's experience with Bristol-Myers Squibb's Serzone is one indication that the agency needs greater enforcement power for postmarketing commitments, Rep. Bart Stupak (D-Mich.) said
You may also be interested in...
PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization
PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization
Postmarketing Study Final Reports To Be Reviewed Within 12 Months – FDA
FDA plans to review final drug postmarketing study reports submitted by manufacturers within 12 months